Zydus Lifesciences Plans To Launch Injection For Diabetes And Obesity On Day 1 Of Patent Expiry

Zydus Lifesciences is set to launch its Semaglutide injection, a treatment aimed at managing Type 2 Diabetes Mellitus and obesity, immediately upon the expiration of its patent. This move follows the approval granted by the Drug Controller General of India (DCGI) for both the manufacturing and marketing of the drug. Semaglutide has gained prominence in the medical community for its effectiveness in controlling blood sugar levels and aiding weight loss among patients with diabetes. With India's rising prevalence of diabetes and obesity, Zydus Lifesciences' entry into this market is timely, offering a potentially significant health solution to millions. The company aims to provide an affordable alternative to existing treatments, thereby improving accessibility for patients in need. This strategic launch not only positions Zydus ahead of competitors but also reflects the company's commitment to addressing critical health issues in India, where lifestyle-related diseases are on the rise.